These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 34044804)
1. Persistent Newcastle disease virus infection in bladder cancer cells is associated with putative pro-survival and anti-viral transcriptomic changes. Chan LC; Kalyanasundram J; Leong SW; Masarudin MJ; Veerakumarasivam A; Yusoff K; Chan SC; Chia SL BMC Cancer; 2021 May; 21(1):625. PubMed ID: 34044804 [TBL] [Abstract][Full Text] [Related]
2. Analysis of PPI networks of transcriptomic expression identifies hub genes associated with Newcastle disease virus persistent infection in bladder cancer. Ahmad U; Abdullah S; Chau M; Chia SL; Yusoff K; Chan SC; Ong TA; Razack AH; Veerakumarasivam A Sci Rep; 2023 May; 13(1):7323. PubMed ID: 37147328 [TBL] [Abstract][Full Text] [Related]
3. Newcastle disease virus mediated apoptosis and migration inhibition of human oral cancer cells: A probable role of β-catenin and matrix metalloproteinase-7. Morla S; Kumar A; Kumar S Sci Rep; 2019 Jul; 9(1):10882. PubMed ID: 31350432 [TBL] [Abstract][Full Text] [Related]
4. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Fournier P; Bian H; Szeberényi J; Schirrmacher V Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477 [TBL] [Abstract][Full Text] [Related]
5. Newcastle disease virus induces pro-inflammatory conditions and type I interferon for counter-acting Treg activity. Fournier P; Arnold A; Wilden H; Schirrmacher V Int J Oncol; 2012 Mar; 40(3):840-50. PubMed ID: 22102168 [TBL] [Abstract][Full Text] [Related]
6. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405 [TBL] [Abstract][Full Text] [Related]
7. Safety and clinical usage of newcastle disease virus in cancer therapy. Lam HY; Yeap SK; Pirozyan MR; Omar AR; Yusoff K; Suraini AA; Abd-Aziz S; Alitheen NB J Biomed Biotechnol; 2011; 2011():718710. PubMed ID: 22131816 [TBL] [Abstract][Full Text] [Related]
8. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Schirrmacher V Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571 [TBL] [Abstract][Full Text] [Related]
9. Different responses of human pancreatic adenocarcinoma cell lines to oncolytic Newcastle disease virus infection. Buijs PR; van Eijck CH; Hofland LJ; Fouchier RA; van den Hoogen BG Cancer Gene Ther; 2014 Jan; 21(1):24-30. PubMed ID: 24384773 [TBL] [Abstract][Full Text] [Related]
10. Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Biswas M; Kumar SR; Allen A; Yong W; Nimmanapalli R; Samal SK; Elankumaran S Viral Immunol; 2012 Aug; 25(4):268-76. PubMed ID: 22808996 [TBL] [Abstract][Full Text] [Related]
11. Newcastle disease virus: a promising agent for tumour immunotherapy. Zhao L; Liu H Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810 [TBL] [Abstract][Full Text] [Related]
12. Oncolytic therapy and gene therapy for cancer: recent advances in antitumor effects of Newcastle disease virus. Huang Z; Liu M; Huang Y Discov Med; 2020; 30(159):39-48. PubMed ID: 33357361 [TBL] [Abstract][Full Text] [Related]
13. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model. He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745 [TBL] [Abstract][Full Text] [Related]
14. Oncolytic Newcastle disease virus induced degradation of YAP through E3 ubiquitin ligase PRKN to exacerbate ferroptosis in tumor cells. Sun Y; Tang L; Kan X; Tan L; Song C; Qiu X; Liao Y; Nair V; Ding C; Liu X; Sun Y J Virol; 2024 Mar; 98(3):e0189723. PubMed ID: 38411946 [TBL] [Abstract][Full Text] [Related]
15. Newcastle disease virus LaSota strain induces apoptosis and activates the TNFα/NF-κB pathway in canine mammary carcinoma cells. Wang J; Li M; Li M Vet Comp Oncol; 2023 Sep; 21(3):520-532. PubMed ID: 37282822 [TBL] [Abstract][Full Text] [Related]
16. Viability reduction and Rac1 gene downregulation of heterogeneous ex-vivo glioma acute slice infected by the oncolytic Newcastle disease virus strain V4UPM. Mustafa Z; Shamsuddin HS; Ideris A; Ibrahim R; Jaafar H; Ali AM; Abdullah JM Biomed Res Int; 2013; 2013():248507. PubMed ID: 23586025 [TBL] [Abstract][Full Text] [Related]
17. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977 [TBL] [Abstract][Full Text] [Related]
18. Transcriptomic analysis of chicken immune response to infection of different doses of Newcastle disease vaccine. Guo LX; Nie FR; Huang AQ; Wang RN; Li MY; Deng HY; Zhou YZ; Zhou XM; Huang YK; Zhou J; Ji YD Gene; 2021 Jan; 766():145077. PubMed ID: 32941951 [TBL] [Abstract][Full Text] [Related]
19. Gene expression profiling in PC12 cells infected with an oncolytic Newcastle disease virus strain. Balogh A; Bátor J; Markó L; Németh M; Pap M; Sétáló G; Müller DN; Csatary LK; Szeberényi J Virus Res; 2014 Jun; 185():10-22. PubMed ID: 24637408 [TBL] [Abstract][Full Text] [Related]
20. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]